W3H Stock Price and Chart — FWB:W3H
This article provides details on Ceribell, Inc. (W3H) stock traded on the Frankfurt Stock Exchange, including key financial metrics, upcoming earnings, and analyst ratings. It highlights the company's focus on medical technology for neurological conditions, its products like Point-of-Care EEG, and its presence in various ETFs. The article also includes a Q&A section addressing common investor queries regarding the stock.
Ceribell director William Burke sells $43,786 in company stock. By Investing.com
William W. Burke, a director at Ceribell, Inc. (NASDAQ: CBLL), sold 2,207 shares of company stock for $43,786 on June 30, 2026, through a Rule 10b5-1 trading plan. Despite a recent 1.4% stock gain, InvestingPro suggests the stock is overvalued. Ceribell, a medical technology company with a $759 million valuation, reported strong Q1 2026 revenue growth of 29% but missed EPS estimates, leading to a lowered price target from Canaccord.
Price to book forward of CeriBell, Inc. – NASDAQ:CBLL
This page from TradingView provides financial information for CeriBell, Inc. (NASDAQ:CBLL), specifically focusing on its "Price to book forward" metric. The article is a stub, indicating that the detailed financial data for this specific metric was not fully loaded or is presented elsewhere on the platform. It serves as a placeholder within the financial overview for the company.
Cost of goods sold of Ceribell, Inc. – TRADEGATE:W3H
This article provides access to the cost of goods sold for Ceribell, Inc. (W3H) on the Tradegate Exchange. It highlights the financial data available through TradingView, noting that the market is currently closed with no trades. The content also lists various data providers and copyright information.
Form 4 CeriBell Inc For: 2 July By Investing.com
The article "Form 4 CeriBell Inc For: 2 July By Investing.com" reports on a Form 4 filing for CeriBell Inc (CBLL) dated July 2, 2026. The stock symbol CBLL is noted with a -2.25% change. The content primarily consists of market data, indices, and financial instrument prices.
Preferred dividends of Ceribell, Inc. – FWB:W3H
This article concerns the preferred dividends of Ceribell, Inc., traded on the Frankfurt Stock Exchange under the ticker W3H. The content is presented within the TradingView platform, which provides financial data and tools for market analysis. The article displays a section for "Preferred dividends" with fields for "Period," "Value," "Change," and "Change %," though no specific dividend data is visible in the provided text.
Enterprise value to revenue forward of CeriBell, Inc. – NASDAQ:CBLL
This article provides financial information for CeriBell, Inc. (NASDAQ: CBLL) focusing on its enterprise value to revenue forward. It appears to be a stub or a report snippet from TradingView, indicating no current trades and directing users to more detailed financial data, news, and technical analysis on their platform.
Net income before discontinued operations of Ceribell, Inc. – FWB:W3H
The article focuses on the "Net income before discontinued operations" for Ceribell, Inc. (FWB:W3H) on the Frankfurt Stock Exchange, as tracked by TradingView. It appears to be a financial data page rather than a news article, displaying a specific financial metric for the company.
Ceribell, Inc. Cash Flow – FWB:W3H
This article provides key cash flow information for Ceribell, Inc. (FWB:W3H). It highlights that the company's free cash flow for Q1 2026 was -16.81M EUR, and for 2025, it was -35.53M EUR, with operating cash flow at -34.87M EUR. The article includes sections for cash flow from operating, investing, and financing activities, as well as free cash flow, indicating detailed financial reporting for multiple years.
Price to book forward of Ceribell, Inc. – FWB:W3H
This article focuses on the "Price to book forward" financial metric for Ceribell, Inc. (FWB:W3H) on the Frankfurt Stock Exchange, as presented on TradingView. The page displays the company's identifier, market status, and offers various financial and community-related data. It indicates that no trades have occurred for this listing, and data is provided by ICE Data Services and FactSet.
Director William Burke Sells 2,207 Shares of CeriBell Inc (CBLL)
William Burke, a Director at CeriBell Inc (CBLL), sold 2,207 shares of the company on June 30, 2026, reducing his total holdings to 23,022 shares. Over the past year, CeriBell Inc has seen 49 insider sells and no insider buys. The company's stock was trading at $19.84 per share on the day of the sale, resulting in a market cap of $752.782 million.
Ceribell director William Burke sells $43,786 in company stock.
Ceribell director William Burke sold 2,207 shares of company stock for $43,786 on June 30, 2026, executed via a Rule 10b5-1 trading plan. Following the sale, Burke retains 23,022 shares. While the medical technology company shows strong revenue growth, InvestingPro analysis indicates the stock may be overvalued.
Form 4 CeriBell Inc For: 2 July By Investing.com
This article from Investing.com announces the filing of Form 4 for CeriBell Inc. on July 2. The content appears to be a stub or an auto-generated placeholder, as it repeats the title multiple times and lacks substantive detail beyond the initial announcement. It includes market data for various indices, commodities, and currencies, as well as a list of popular articles and market movers.
Ceribell director William Burke sells $43,786 in company stock. By Investing.com
Ceribell director William W. Burke recently sold 2,207 shares of the company's common stock for $43,786, executed under a Rule 10b5-1 trading plan. Following the transaction, Burke directly holds 23,022 shares. The company experienced robust revenue growth of 33% over the last twelve months, despite reporting an earnings per share loss of $0.52 in Q1 2026.
Ceribell(CBLL.US) Insider Sells US$4.07 Million in Common Stock
A significant insider stock sale at Ceribell (CBLL.US) has been reported, with an insider divesting common stock valued at $4.07 million. This transaction could be of interest to investors monitoring insider activity as an indicator of company performance or future outlook.
Form 144 Ceribell For: 30 June By Investing.com
This article announces the filing of Form 144 for Ceribell on June 30, published by Investing.com. It is a brief, factual update indicating a regulatory filing has occurred for the company. The content primarily consists of navigational elements and advertisements typical of a financial news portal.
CeriBell Inc (CBLL) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of CeriBell Inc (CBLL), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. Currently, CBLL's price momentum score is 8.68, and the stock is trading between a resistance level of 21.50 and a support level of 17.72. The analysis indicates a "Buy" signal based on moving averages and other technical indicators, with multiple buy signals observed from MA5 to MA200.
Ceribell, Inc. (CBLL) reports Q1 loss, beats revenue estimates
Ceribell, Inc. (CBLL) reported its first-quarter financial results, showing a loss per share but exceeding revenue expectations. This indicates that while the company is still operating at a loss, its sales performance was stronger than analysts had predicted for the quarter.
Ceribell, Inc. Actuals & Estimates (NASDAQ:CBLL)
This article provides an overview of Ceribell, Inc. (NASDAQ:CBLL) stock performance, financial actuals, and analyst estimates. It highlights recent price movements, market capitalization, upcoming earnings reports, and analyst forecasts for its future stock price. The article also addresses frequently asked questions regarding the company's financial data and investment considerations.
CBLL Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast for CeriBell, Inc. (CBLL) stock, including analyst price targets, historical performance, and key financial metrics. It highlights that analysts have a max estimated future price of $32.00 and a min estimate of $24.00, while the stock has shown recent upward trends in price. The company's earnings, revenue, market capitalization, and upcoming earnings report date are also presented.
CeriBell Inc (CBLL) Financial Health: Profitability & Balance Sheet Analysis
CeriBell Inc (CBLL) currently holds a financial score of 7.27, ranking 95th out of 203 in the Healthcare Equipment & Supplies industry, indicating robust financial health with low operating efficiency. The company recently reported a quarterly revenue of $26.49M, a 29.30% year-over-year increase, and a net profit increase of 54.47% year-over-year. While overall financial health is strong, detailed data for quality of earnings, operational efficiency, growth potential, and shareholder returns are not yet disclosed by the company.
CBLL Stock News Today | Earnings, Events & Price Alerts
This page provides a compilation of recent news and events for CeriBell (CBLL) stock, including financial reports, strategic announcements, and FDA designations. Key highlights include strong Q1 2026 earnings with revenue growth, positive Q4 2025 results, and the receipt of FDA Breakthrough Device Designation for its stroke detection monitor. The company also announced an upcoming presentation at the J.P. Morgan Healthcare Conference and a partnership to advance cardiac imaging.
CeriBell Inc (CBLL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on CeriBell Inc (CBLL)'s dividend and stock split history, indicating that no dividend payouts have been distributed over the past five years and no stock split events have been recorded. It presents current stock performance data, including market cap and recent price changes.
CeriBell Inc (CBLL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
CeriBell Inc (CBLL) generated a total revenue of $89.06 million, with 75.60% ($67.33 million) coming from EEG recorders and headbands, and 24.40% ($21.73 million) from EEG portal and Clarity subscriptions. All reported revenue for the company came from the United States. This data was updated on Monday, April 6th, and covers FY2025 across its quarters, as well as FY2024 and FY2023.
Ceribell | 4: Statement of changes in beneficial ownership of securities-Director Taylor Joseph Michael
This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Ceribell, listing Director Taylor Joseph Michael. The Form 4 is a regulatory filing indicating changes in stock ownership by company insiders.
Insider Sell Alert: Joseph Taylor Sells 5,500 Shares of CeriBell Inc (CBLL)
Joseph Taylor, a Director at CeriBell Inc (CBLL), sold 5,500 shares of the company on June 11, 2026. This transaction is part of a broader trend of insider selling at CeriBell, with 50 insider sells and no buys over the past year. Shares were trading at $18.41, and investors are advised to consider this activity alongside other valuation metrics.
Ceribell director Joseph Taylor sells $101,255 in common stock
Ceribell director Joseph Michael Taylor sold 5,500 shares of the company's common stock for $101,255 on June 11, 2026. This transaction occurred at a time when the stock appears overvalued according to InvestingPro analysis. Despite the insider sale, Ceribell maintains a strong balance sheet with more cash than debt and impressive gross profit margins of 87.72%.
Ceribell CEO Chao sells $714,870 in common stock
Ceribell CEO Chao recently sold $714,870 worth of the company's common stock after exercising options, as part of a Rule 10b5-1 trading plan. The transactions occurred shortly after Ceribell's shares saw a 7.68% return, though the company is noted as overvalued and unprofitable despite strong gross profit margins and revenue growth. Following these sales and exercises, Ms. Chao directly and indirectly holds over 1.1 million shares in Ceribell.
Ceribell Insider Sold Shares Worth $714,870, According to a Recent SEC Filing
An insider at Ceribell recently sold shares totaling $714,870, as disclosed in a recent SEC filing. The transaction involved 11,500 shares being sold at an average price of $62.16 each. Following this sale, the insider still directly owns 70,724 shares of the company.
Ceribell CEO Chao sells $714,870 in common stock By Investing.com
Ceribell CEO Chao recently sold $714,870 worth of the company's common stock after exercising stock options. The sales were made under a Rule 10b5-1 trading plan, coinciding with a strong week for Ceribell shares, though the stock is considered overvalued by InvestingPro. Ceribell (NASDAQ:CBLL) reported a 29% revenue increase in Q1 2026 but missed earnings expectations, leading to a lowered price target from Canaccord.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are showing bullish sentiment towards the healthcare sector, particularly for Ceribell, Inc. (CBLL) and Nurix Therapeutics (NRIX). TD Cowen's Josh Jennings reiterated a Buy rating for Ceribell with a $29.00 price target, while Needham's Gil Blum maintained a Buy rating for Nurix Therapeutics with a $34.00 price target, both indicating significant upside potential according to their respective firms.
Ceribell Insider Sold Shares Worth $714,870, According to a Recent SEC Filing
An insider at Ceribell, Inc. sold shares valued at $714,870, as reported in a recent SEC filing. The article provides this key financial transaction, alongside the company's stock performance and a summary of recent news and financial updates for Ceribell.
Ceribell CEO Chao sells $714,870 in common stock
Ceribell CEO Chao Xingjuan sold $714,870 worth of common stock on June 8, 2026, after exercising stock options to acquire 25,000 shares. These transactions were executed under a Rule 10b5-1 trading plan, coinciding with a 7.68% stock return for Ceribell over the past week. The company, despite strong revenue growth and gross profit margins, remains unprofitable, with recent analyst downward revisions for earnings.
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Ceribell announced a new publication in Critical Care Medicine demonstrating that its Clarity AI algorithm, measuring seizure burden, is linked to neurological outcomes in patients. The study found that higher AI-detected seizure burden is associated with increased odds of disability and poorer functional outcomes at discharge. This research reinforces the utility of the Ceribell System as a clinical decision-making tool for rapid neurodiagnostics in critical care settings.
Ceribell Announces New Critical Care Medicine Publication
Ceribell announced a new publication in Critical Care Medicine demonstrating that its Clarity AI algorithm, which measures seizure burden from Point-of-Care EEG, correlates with patient functional outcomes. The study involved 359 adult patients and found that higher AI-detected seizure burden was linked to increased severe disability and poorer functional outcomes at discharge. This research reinforces the utility of the Ceribell System as a clinical decision-making tool for rapid and actionable neurodiagnostics in critical care settings.
FDA-approved ceribell egg shortens seizure diagnosis by monitoring brain activity
An FDA-approved device called Ceribell Egg is designed to shorten the diagnosis time for seizures by continuously monitoring brain activity. The article from CBS Baltimore highlights this new technology.
AI in the ICU: Ceribell's New Study Cements Link to Patient Outcomes
A new study published in Critical Care Medicine demonstrates that Ceribell's AI-powered algorithm, Clarity, can predict patient outcomes by measuring seizure activity, showing that high seizure burden significantly increases the risk of death or severe disability. This technology provides rapid, real-time detection of silent seizures, offering substantial clinical benefits for critically ill patients and economic savings for hospitals due to reduced length of stay. Ceribell, following a successful IPO and multiple FDA clearances, is solidifying its position in the neurodiagnostics market with this validated technology that promises to transform neurological care.
Ceribell Announces New Critical Care Medicine Publication
Ceribell announced a new publication in Critical Care Medicine showing that its Clarity AI algorithm, which measures seizure burden from point-of-care EEG, is linked to patient neurological outcomes. The study indicated that a higher AI-detected seizure burden is associated with increased odds of disability and death at discharge. These findings support the utility of the Ceribell System as a clinical decision-making tool in emergency and intensive care settings, emphasizing the importance of rapid intervention.
AI EEG tool links ICU seizure burden to death and disability risk
Ceribell (Nasdaq: CBLL) announced a new publication in Critical Care Medicine demonstrating a link between its Clarity AI seizure-burden metric and neurological outcomes. A multicenter study found that higher AI-detected seizure burden was significantly associated with increased odds of severe disability or death in 359 adult patients. This research reinforces the utility of Ceribell's AI-powered Point-of-Care EEG system for clinical decision support in acute care settings.
William Blair Maintains Ceribell(CBLL.US) With Buy Rating
William Blair has reiterated its Buy rating for Ceribell (CBLL.US). This endorsement suggests a positive outlook from the firm regarding the company's stock performance.
Ceribell Announces Director Elections at 2026 Annual Meeting
Ceribell, Inc. held its 2026 Annual Meeting of Stockholders where Josef Parvizi, M.D., Ph.D., and Rebecca Robertson were elected as Class II directors. Shareholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. An analyst rating on CBLL stock is a Buy with a $28.00 price target, though TipRanks’ AI Analyst, Spark, rates it Neutral due to persistent losses and weak momentum despite strong revenue growth.
CeriBell (CBLL) 10K Form and Latest SEC Filings 2026
This article provides a comprehensive overview of CeriBell's (CBLL) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents, dating back to 2024. It highlights the importance of these filings for investors to access verified financial data and track company events and insider trading. The most recent filing was a Form 4 on June 4, 2026, detailing an ownership change.
CBLL - Ceribell Inc Stock Price and Quote
This article provides comprehensive financial data for Ceribell Inc. (CBLL), a medical technology company specializing in AI-powered EEG for neurological conditions. It details stock performance, key financial metrics, insider transactions, and a timeline of company news and analyst ratings. The data underscores Ceribell's rapid growth and innovation in the medtech industry, including multiple FDA clearances and a successful IPO.
InvestingPro’s Fair Value warned of CeriBell crash 17 months ago By Investing.com
InvestingPro's Fair Value models accurately predicted a significant crash for CeriBell, Inc. (NASDAQ:CBLL) 17 months ago, identifying it as overvalued at $29.22 with an intrinsic value of $18.83. Since then, the stock has plummeted 42% to $16.96, validating the warning. The analysis highlighted CeriBell's heavy cash burn and valuation disconnect despite positive catalysts, demonstrating the precision of InvestingPro's multi-factor approach in identifying mispriced stocks.
CeriBell (CBLL) Earnings Date and Reports 2026 $CBLL
CeriBell (CBLL) announced its Q1 2026 earnings on May 11, 2026, reporting an EPS of -$0.52, missing consensus estimates by $0.13, while revenue of $26.49 million exceeded expectations. The company's next earnings report for Q2 2026 is estimated for August 4, 2026. CeriBell's annual revenue stands at $89.06 million with a net income of -$53.41 million, and analysts expect EPS to improve from ($1.69) to ($1.16) in the next year.
CeriBell (Nasdaq:CBLL) - Aandelenanalyse
This article provides a stock analysis of CeriBell (Nasdaq:CBLL), a medical technology company specializing in AI-enabled point-of-care EEG solutions. The company's stock is currently trading at US$18.74, with analysts suggesting it is 30.6% undervalued with a target price of US$27. Key developments include FDA clearances for LVO stroke detection, delirium monitoring, and neonatal seizure detection, alongside raised revenue guidance for 2026. However, the company remains unprofitable and has seen significant insider selling.
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
Ceribell, an innovator in medical technology, has announced its participation in the 46th Annual William Blair Growth Stock Conference. This event will feature Ceribell's management engaging in investor meetings and a presentation. The conference provides a platform for growth-oriented companies to connect with investors.
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
Ceribell, Inc. announced that its CEO and Co-founder, Jane Chao, Ph.D., will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026. The presentation will cover the company's focus on transforming the diagnosis and management of patients with serious neurological conditions. A live and archived webcast will be available on Ceribell's investor relations website.
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
Ceribell, Inc. announced that its CEO and Co-founder, Jane Chao, Ph.D., will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026. The presentation will details on the company's focus on transforming the diagnosis and management of patients with serious neurological conditions. A live and archived webcast will be available on Ceribell's investor relations website.
Bank of America Securities Remains a Buy on Ceribell, Inc. (CBLL)
Bank of America Securities reiterated a Buy rating on Ceribell, Inc. (CBLL) with an average price target of $28.50, suggesting a 74.85% upside. This comes despite negative insider sentiment, with increased insider selling recently. The company's latest quarterly revenue was $26.49 million, with a GAAP net loss of $19.74 million.
